PACB Jun 2020 1.000 put

OPR - OPR Delayed Price. Currency in USD
0.0500
0.0000 (0.00%)
As of 12:43PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.0500
Open0.0500
Bid0.0000
Ask0.1000
Strike1.00
Expire Date2020-06-19
Day's Range0.0500 - 0.0500
Contract RangeN/A
Volume2
Open Interest2
  • Thomson Reuters StreetEvents

    Edited Transcript of PACB earnings conference call or presentation 6-Feb-20 9:30pm GMT

    Q4 2019 Pacific Biosciences of California Inc Earnings Call

  • Coronavirus update: At least 724 deaths, WHO to send mission, American dies in China
    MarketWatch

    Coronavirus update: At least 724 deaths, WHO to send mission, American dies in China

    There are now 34,822 confirmed cases of coronavirus worldwide and at least 724 people have died, according to the latest figures from the World Health Organization (WHO).

  • GlobeNewswire

    Pacific Biosciences Announces Retirement of Michael Phillips, SVP of Research and Development

    Pacific Biosciences of California, Inc. (PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that Michael Phillips has decided to retire from his role as the company’s Senior Vice President of Research and Development as of April 1, 2020. Mr. Phillips has directed the development of PacBio’s technology since joining the company in 2005.

  • Pacific Biosciences (PACB) Reports Break-Even Earnings in Q4
    Zacks

    Pacific Biosciences (PACB) Reports Break-Even Earnings in Q4

    Pacific Biosciences (PACB) expects softness in first-quarter consumable sales.

  • Pacific Biosciences of California (PACB) Reports Break-Even Earnings for Q4
    Zacks

    Pacific Biosciences of California (PACB) Reports Break-Even Earnings for Q4

    Pacific Biosciences (PACB) delivered earnings and revenue surprises of 100.00% and 9.79%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Pacific Biosciences Announces Fourth Quarter and Annual 2019 Financial Results

    MENLO PARK, Calif., Feb. 06, 2020 -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its fourth quarter and year ended December 31,.

  • ACCESSWIRE

    Pacific Biosciences of California, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 6, 2020 / Pacific Biosciences of California, Inc. (NASDAQ:PACB) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February ...

  • Pacific Biosciences of California (PACB) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks

    Pacific Biosciences of California (PACB) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Bloomberg

    Big Tech Gets Put on Guard by Antitrust Police

    (Bloomberg Opinion) -- When the world’s competition police reflect on big tech’s dealmaking over the past 15 years, you could forgive them for wondering what might have been. If Facebook Inc. hadn’t acquired WhatsApp or Instagram, or if Google hadn’t bought YouTube or DoubleClick, would there be stronger competition for the two Silicon Valley firms?It certainly seems that regulators, particularly in the U.K., are eager to avoid repeat scenarios where companies grab outsize control of an emerging market before it’s clear exactly how important or big that market may be. That’s why a 6.1 billion-pound ($8 billion) food delivery takeover may have broader implications for tech giants’ dealmaking-to-come.Britain’s Competition and Markets Authority is reviewing the Dutch firm Takeaway.com NV’s planned acquisition of Just Eat Plc, the U.K.’s online marketplace for restaurant delivery. It’s a remarkable step, given that Takeaway.com no longer has a British business, and so the two firms don’t currently compete, at least not in the U.K. The regulator, the CMA, is instead pondering hypotheticals. It’s deliberating whether, without a deal, Takeaway.com might still otherwise enter the market and add a healthy dose of competition.The move underscores a recent approach that could make it more difficult for tech giants to make acquisitions, even small ones. (Together, they’ve bought more than 250 companies in the last six years.) Companies might not obviously compete with the firm acquiring them, but the U.K. watchdog is increasingly taking into account the possibility they could become a competitor at some later stage. It seems to have listened to the findings of the government-commissioned review into digital competition last year by Jason Furman, previously economic adviser to former U.S. President Barack Obama, which recommended that the CMA should take “more frequent and firmer action to challenge mergers that could be detrimental to consumer welfare through reducing future levels of innovation and competition.”Across the Atlantic, DNA-sequencing firm Illumina Inc.’s scuppered $1.2 billion acquisition of smaller peer Pacific Biosciences of California Inc. also illustrates the challenge. Both firms are active in slightly different parts of the market, so do not directly compete: Illumina currently focuses on so-called short-read sequencing platforms, while PacBio’s expertise is in long-reads. Yet antitrust authorities in both the U.K. and U.S. pushed back against the deal because of concerns that Illumina would decide against developing its own long-read offering further down the line, according to Bloomberg Intelligence analyst Aitor Ortiz. The firms called the deal off earlier this month.It’s healthy that technology deals are likely to attract more scrutiny. Acquisitions sometimes look like a catch-and-kill strategy: buying a startup that could become a rival before it's able to do so without necessarily using it to augment the business directly. For example, back in 2017, Facebook bought the fast-growing teen app tbh, before shutting it down just eight months later, citing low usage.But doing so presents a potential challenge for the CMA: ensuring that the U.K. remains an attractive place to found technology firms. Venture capitalists and big companies themselves often argue that a lot of startups are founded with the intention of ultimately selling themselves to a larger rival. If that exit strategy disappears, runs the argument, then they might decide to set up shop elsewhere.So far, it’s too early to determine whether that argument has any merit. And analysts still expect the Takeaway.com-Just Eat deal to complete, albeit with a slight delay. But because the CMA has the authority to impose remedies without a court case, unlike the U.S.’s Federal Trade Commission, technology firms have good reason to be wary.To contact the author of this story: Alex Webb at awebb25@bloomberg.netTo contact the editor responsible for this story: Melissa Pozsgay at mpozsgay@bloomberg.netThis column does not necessarily reflect the opinion of Bloomberg LP and its owners.Alex Webb is a Bloomberg Opinion columnist covering Europe's technology, media and communications industries. He previously covered Apple and other technology companies for Bloomberg News in San Francisco.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • GlobeNewswire

    Pacific Biosciences of California, Inc. Fourth Quarter 2019 Financial Results Call

    MENLO PARK, Calif., Jan. 21, 2020 -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Fourth Quarter 2019 Financial.

  • Sequencing giant Illumina scraps $1.2 billion PacBio acquisition
    American City Business Journals

    Sequencing giant Illumina scraps $1.2 billion PacBio acquisition

    Genetic sequencing giant Illumina Inc. has nixed its $1.2 billion acquisition attempt of Menlo Park's Pacific Biosciences amid intense regulator scrutiny. San Diego-based Illumina announced the all-cash deal to purchase its smaller competitor in 2018, but it has faced an uphill battle to convince regulators in the U.S. and Europe. In October, antitrust regulators in the UK put out a statement of concern about the proposed merger given Illumina's immense market power in the highly-concentrated DNA sequencing industry.

  • TheStreet.com

    U.S. Kills Iranian General, Oil Prices Surge, FOMC to Release Minutes - 5 Things You Must Know Friday

    U.S. stock futures sink and oil prices surge after a U.S. military strike kills Gen. Qassem Soleimani, a top Iranian general; the U.S. economic calendar includes the ISM Manufacturing Index for December and minutes from the Federal Reserve's Dec. 10-11 meeting; Illumina abandons $1.2 billion acquisition of Pacific Biosciences.

  • MarketWatch

    Illumina, Pacific Biosciences drop $1.2 billion merger agreement

    Illumina Inc. and Pacific Biosciences of California Inc. on Thursday said they have agreed to drop plans to merge. Under the merger agreement, announced Nov. 1, Illumina would have paid $1.2 billion in cash for Pacific Biosciences. The news sent Pacific Biosciences shares down 3% in after-hours trading. The lengthy regulatory approval process required for the transaction "has already been subject to and continued uncertainty of the ultimate outcome," the companies said in a joint news release. As part of the merger agreement, Illumina will pay Pacific Biosciences a termination fee of $98 million. The announcement was made after markets closed.

  • Business Wire

    Illumina and Pacific Biosciences Announce Termination of Merger Agreement

    Illumina, Inc. (NASDAQ:ILMN) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that they have mutually agreed to terminate their merger agreement, previously announced on November 1, 2018, under which Illumina would acquire Pacific Biosciences at a fully diluted enterprise value of approximately $1.2 billion in an all-cash transaction.

  • Here's Why You Should Retain Pacific Biosciences Stock Now
    Zacks

    Here's Why You Should Retain Pacific Biosciences Stock Now

    Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.

  • MarketWatch

    Pacific Biosciences stock falls on FTC challenge to Illumina deal

    Shares of Pacific Biosciences of California Inc. tumbled 3% in morning trading the day after the Federal Trade Commission announced plans to challenge Illumina Inc.'s plans to buy the genetic sequencing company. The regulator said Dec. 17 that Illumina is trying to "unlawfully maintain its monopoly in the U.S. market for next-generation DNA sequencing" by buying Pacific, a potential competitor. Shares of Illumina, which proposed to buy Pacific Biosciences for $1.2 billion in November 2018, are down 0.3%. "We strongly disagree with the FTC's decision and will continue to work through the regulatory approval process as we consider next steps," an Illumina spokesperson said in an email. Year-to-date, Pacific's stock is down 30%, while shares of Illumina have gained 7%. The Health Care Select Sector SPDR Fund exchange-traded fund has gained 17% year-to-date.

  • Benzinga

    The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 17) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: ...

  • Hedge Funds Have Never Been This Bullish On Pacific Biosciences of California, Inc. (PACB)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Pacific Biosciences of California, Inc. (PACB)

    Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]

  • Pacific Biosciences (PACB) Up 2.7% Since Last Earnings Report: Can It Continue?
    Zacks

    Pacific Biosciences (PACB) Up 2.7% Since Last Earnings Report: Can It Continue?

    Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Here's Why You Should Hold on to Pacific Biosciences Stock
    Zacks

    Here's Why You Should Hold on to Pacific Biosciences Stock

    Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.

  • Options Traders Expect Huge Moves in Pacific Biosciences (PACB) Stock
    Zacks

    Options Traders Expect Huge Moves in Pacific Biosciences (PACB) Stock

    Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately.

  • Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates
    Zacks

    Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates

    Pacific Biosciences (PACB) gains from solid segmental contributions in the third quarter.